Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y/Y. CEO Patrick Holt shares operational progress, including European market signs. Amarin initiates a $50 million buyback, on track for $40 million in annual savings.
Why Is Amarin Stock Trading Lower After Q4 Earnings? biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
The stock of Amarin Corporation plc (NASDAQ: AMRN) has increased by 0.99 when compared to last closing price of 1.01.Despite this, the company has seen a gain of 0.99% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-12 that DUBLIN, Ireland and BRIDGEWATER, N.J., Se
VAZKEPA® (icosapent ethyl) accepted by the Scottish Medicines Consortium (SMC) for restricted use within NHSScotland, as secondary prevention in adult statin-treated patients at high cardiovascular risk1 VAZKEPA® already commercially available in England, Wales, and Northern Ireland where NICE recommended its reimbursement and use across the National Health Service (NHS) in July 2022 Amarin now working with Health Boards across Scotland to secure formulary inclusion and ensure eli